Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1290 articles
A landmark 2025 review maps the molecular and cellular mechanisms driving immune aging, linking inflammaging to cancer, neurodegeneration, and infection.
A 2026 review evaluates how two common dietary flavonoids target senescent cells, potentially slowing aging and age-related disease.
A new study pinpoints chemotherapy-induced senescent bone marrow cells as the culprit behind bone loss, and shows senolytics can prevent it.
Tiny vesicles extracted from plants show remarkable potential to repair tissues and slow aging with high safety and low cost.
Plant-derived exosome-like nanovesicles (PENs) carry lipids, proteins, and RNA with potent anti-aging and skin-repair properties.
The neutrophil-to-lymphocyte ratio rises with age and predicts disease risk — and centenarians show a slower increase, hinting at immune resilience.
Rockefeller scientists mapped epigenomic aging across 7M cells in 21 tissues, uncovering coordinated, program-like shifts that may unlock new therapies.
SimonMed is expanding AI imaging tools that extract cardiovascular, bone, and spine risk data from scans patients already get.
Twenty global teams win funding and data access to find new ALS drug targets using AI and multi-omics — a potential model for all aging diseases.
Pegsebrenatide, a long-acting GLP-1 receptor agonist, is now in human trials targeting neurodegeneration in progressive MS — with broad longevity implications.
Epigenetic clock pioneer Steve Horvath explains why the field is converging on validated biomarkers to make longevity medicine actionable.
From a massive family study of centenarians to a paradigm shift in how aging is measured, longevity science is evolving fast.
